University of Hull logo

CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study (2018)
Journal Article
Jackson, G., Gabe, R., Johnson, M., Date, K., Harman, D., Maraveyas, A., …Lind, M. J. (2019). CAMERA - complete assessment of elderly patients with cancer: A non-randomised feasibility study. Journal of Geriatric Oncology, 10(1), 175-177. doi:10.1016/j.jgo.2018.07.005

One of the primary risk factors in the development of cancer is older age. The demographic shift to an ageing population has given rise to an increased number of older patients with cancer. The extreme heterogeneity within this population renders app... Read More

MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma (2017)
Journal Article
Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Molecular Therapy - Nucleic Acids, 8(15 September 2017), 317-329. doi:10.1016/j.omtn.2017.07.001

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis, and most patients initially are or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9p21.3, whi... Read More

The effect of emergency presentation on surgery and survival in lung cancer patients in England, 2006–2008 (2015)
Journal Article
Tataru, D., Jack, R. H., Lind, M. J., Møller, H., & Lüchtenborg, M. (2015). The effect of emergency presentation on surgery and survival in lung cancer patients in England, 2006–2008. Cancer epidemiology, 39(4), (612-616). doi:10.1016/j.canep.2015.04.008. ISSN 1877-7821

A large proportion of lung cancer patients in England are diagnosed through an emergency route, which is associated with poorer outcomes. Here, we investigated the association between emergency presentation and the odds of undergoing surgical resecti... Read More

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009 (2013)
Journal Article
Lüchtenborg, M., Riaz, S. P., Lim, E., Page, R., Baldwin, D. R., Jakobsen, E., …Møller, H. (2014). Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009. Thorax, 69(3), (269-273). doi:10.1136/thoraxjnl-2013-203884. ISSN 0040-6376

Introduction: Chemotherapy or chemoradiotherapy is the recommended treatment for small cell lung cancer (SCLC), except in stage I disease where clinical guidelines state there may be a role for surgery based on favourable outcomes in case series. Evi... Read More

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. doi:10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More

Differential proteomics in the search for biomarkers of radiotherapy resistance (2011)
Journal Article
Scaife, L., Hodgkinson, V. C., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Differential proteomics in the search for biomarkers of radiotherapy resistance. Expert Review of Proteomics, 8(4), (535-552). doi:10.1586/EPR.11.32. ISSN 1478-9450

The individualization of radiotherapy treatment would be beneficial for cancer patients; however, there are no predictive biomarkers of radiotherapy resistance in routine clinical use. This article describes the body of work in this field where compa... Read More

Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis (2011)
Journal Article
Hodgkinson, V. C., ELFadl, D., Drew, P. J., Lind, M. J., & Cawkwell, L. (2011). Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. Journal of Proteomics, 74(5), (698-703). doi:10.1016/j.jprot.2011.02.014. ISSN 1874-3919

Antibody microarrays are powerful new tools in the field of comparative proteomics. The success of the biomarker discovery pipeline relies on the quality of data generated in the discovery phase and careful selection of proteins for the verification... Read More

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? (2010)
Journal Article
Agarwal, V., Cawkwell, L., & Lind, M. J. (2011). Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. Cancer Treatment Reviews, 37(7), (533-542). doi:10.1016/j.ctrv.2010.11.004. ISSN 1532-1967

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant... Read More

Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status (2010)
Journal Article
Hodgkinson, V. C., Eagle, G. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2010). Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Letters, 294(1), (13-24). doi:10.1016/j.canlet.2010.01.036. ISSN 0304-3835

This review describes and discusses the advantages and limitations of proteomic approaches in the identification of biomarkers associated with chemotherapy resistance. Both gel-based (two-dimensional polyacrylamide gel electrophoresis) and gel-free (... Read More

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? (2009)
Journal Article
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., …Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), (1194-1207). doi:10.1593/neo.09902. ISSN 1522-8002

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitiviti... Read More

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), (160-165). doi:10.1016/j.lungcan.2009.04.008. ISSN 0169-5002

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Rasch, W., Gaullier, J., Sandvold, M. L., Thomas, H., Aamdal, S., Dueland, S., & Lind, M. J. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta oncologica, 48(1), 137-145. doi:10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More